Abstract:Conversion of arachidonic acid epoxides to diols by soluble epoxide hydrolase (sEH) diminishes the beneficial cardiovascular properties of these epoxyeicosanoids. We therefore examined the possible biochemical consequences of inhibition of sEH and sEH deletion. We hypothesized that decreased sEH expression, would increase mitochondrial integrity, insulin sensitivity, EETs isomers and adipocyte function. To test this hypothesis, we examined the effect of sEH inhibitors on human MSC‐decreased adipocytes as well as sEH deletion in a mouse model treated with either HO‐1 lentiviral‐vector or cobalt protoporphyrin (CoPP) over an 8‐week period. Human MSc synthesized both EETs and EET metabolites (DHETs). MSc‐derived adipocyte treated with Auda, an inhibitor of sEH, exhibited a decreased number of large adipocytes, i.e. inflamed adipocyte but an increased number of healthy adipocytes that display increased levels of adiponectin, HO‐1 and PGC‐1a and decreased levels of TNFa. The addition of 8, 9, 14, and 15 EETs to adipocyte culture resulted in a reduction in large inflamed adipocytes, PPARg, FAS and lipid accumulation. In vivo studies demonstrated that sEH deletion resulted in a significant decrease in body weight and fasting glucose; p <0.05 and increased insulin sensitivity and serum adiponectin levels (p<0.03) and decreased visceral fat (p<0.05). Critically, sEH deletion was manifested by a significant increase in EETs isomers 5, 6; 8, 9; 11, 12; and 14, 15, EETs. Additionally, induction of HO‐1 potentiated the increases of EETs isomers, suggesting that increases antioxidant protected EETs from degradation by ROS. These novel observations highlighted the potential beneficial effects of EETs that resulted in increased mitochondrial integrity, HO‐1‐PGC1a and UCP1 levels. These results provide evidence that sEH deletion preserved vascular homeostasis, increased brown fat phenotype and that both EETs‐agonist and sEH inhibitors may have therapeutic potential in the treatment of metabolic syndrome and dyslipidemia. Support or Funding Information National Institutes of Health grant (HL34300 to NGA) This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Ablation of Soluble Epoxide Hydrolase Expression Increases Beige Fat Over White Fat Through an Increase in Mitochondrial Integrity, Insulin Sensitivity and HO‐1‐PGC1α‐adiponectin in‐vitro and in‐vivo

Pharmacological inhibition or genetic ablation of soluble epoxide hydrolase attenuates obesity-induced nonalcoholic fatty liver disease

CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype

Inhibition of Soluble Epoxide Hydrolase in Mice Promotes Reverse Cholesterol Transport and Regression of Atherosclerosis

Soluble Epoxide Hydrolase Inhibition by t-TUCB Promotes Brown Adipogenesis and Reduces Serum Triglycerides in Diet-Induced Obesity

Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet-Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice

Inhibition of Soluble Epoxide Hydrolase Ameliorates Hyperhomocysteinemia-Induced Hepatic Steatosis by Enhancing Β-Oxidation of Fatty Acid in Mice.

Inhibition of Soluble Epoxide Hydrolase Alleviated Atherosclerosis by Reducing Monocyte Infiltration in Ldlr−/− Mice

Abstract 542: the Effects of Soluble Epoxide Hydrolase Inhibition in Atherogenesis and Atherosclerotic Progression

Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides

Soluble Epoxide Hydrolase: A Potential Target for Metabolic Diseases

Soluble epoxide hydrolase deficiency attenuates lipotoxic cardiomyopathy via upregulation of AMPK-mTORC mediated autophagy

Soluble Epoxide Hydrolase: A Potential Target for Metabolic Diseases.

Soluble epoxide hydrolase inhibition attenuates aortic plaque formation in a murine model of accelerated atherogenesis

Increased Soluble Epoxide Hydrolase Activity Positively Correlates with Mortality in Heart Failure Patients with Preserved Ejection Fraction: Evidence from Metabolomics.

GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans

A Potent Soluble Epoxide Hydrolase Inhibitor, T-Aucb, Modulates Cholesterol Balance and Oxidized Low Density Lipoprotein Metabolism in Adipocytes in Vitro.

A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction

Opposite Effects of Gene Deficiency and Pharmacological Inhibition of Soluble Epoxide Hydrolase on Cardiac Fibrosis

Soluble Epoxide Hydrolase is an Endogenous Regulator of Obesity-Induced Intestinal Barrier Dysfunction and Bacterial Translocation.

Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney